Alignment Healthcare, Inc. (NASDAQ:ALHC) Shares Bought by SG Americas Securities LLC

SG Americas Securities LLC lifted its holdings in shares of Alignment Healthcare, Inc. (NASDAQ:ALHC) by 11.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 49,272 shares of the company’s stock after buying an additional 5,163 shares during the period. SG Americas Securities LLC’s holdings in Alignment Healthcare were worth $554,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. nVerses Capital LLC purchased a new position in Alignment Healthcare during the 3rd quarter worth $95,000. Ballentine Partners LLC acquired a new position in shares of Alignment Healthcare during the fourth quarter worth about $121,000. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Alignment Healthcare during the third quarter worth about $131,000. Creative Planning lifted its position in Alignment Healthcare by 20.0% in the third quarter. Creative Planning now owns 12,442 shares of the company’s stock valued at $147,000 after purchasing an additional 2,072 shares during the period. Finally, Mackenzie Financial Corp boosted its holdings in Alignment Healthcare by 110.0% in the 2nd quarter. Mackenzie Financial Corp now owns 36,526 shares of the company’s stock valued at $286,000 after purchasing an additional 19,129 shares in the last quarter. Hedge funds and other institutional investors own 86.19% of the company’s stock.

Alignment Healthcare Stock Performance

Shares of ALHC opened at $15.39 on Friday. Alignment Healthcare, Inc. has a 12-month low of $4.46 and a 12-month high of $15.82. The stock has a market cap of $2.95 billion, a P/E ratio of -19.99 and a beta of 1.45. The company has a current ratio of 1.60, a quick ratio of 1.60 and a debt-to-equity ratio of 1.82. The company has a 50-day moving average of $12.50 and a two-hundred day moving average of $11.23.

Alignment Healthcare (NASDAQ:ALHC) last issued its quarterly earnings data on Tuesday, October 29th. The company reported ($0.14) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.14). Alignment Healthcare had a negative return on equity of 108.69% and a negative net margin of 5.84%. The firm had revenue of $692.43 million during the quarter, compared to the consensus estimate of $662.11 million. During the same period in the previous year, the firm posted ($0.19) EPS. The company’s quarterly revenue was up 51.6% compared to the same quarter last year. As a group, research analysts predict that Alignment Healthcare, Inc. will post -0.69 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Hakan Kardes sold 14,500 shares of the firm’s stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $14.98, for a total transaction of $217,210.00. Following the sale, the insider now owns 295,444 shares in the company, valued at approximately $4,425,751.12. This trade represents a 4.68 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO John E. Kao sold 90,000 shares of Alignment Healthcare stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $13.42, for a total transaction of $1,207,800.00. Following the completion of the sale, the chief executive officer now directly owns 2,453,100 shares of the company’s stock, valued at $32,920,602. The trade was a 3.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 519,044 shares of company stock valued at $6,634,832. Corporate insiders own 6.60% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on ALHC shares. Barclays raised their price target on Alignment Healthcare from $7.00 to $8.00 and gave the company an “underweight” rating in a report on Wednesday, October 30th. KeyCorp assumed coverage on shares of Alignment Healthcare in a research report on Friday, October 11th. They set a “sector weight” rating on the stock. Stephens reaffirmed an “overweight” rating and set a $17.00 price target on shares of Alignment Healthcare in a research note on Thursday, January 2nd. Stifel Nicolaus raised their price objective on shares of Alignment Healthcare from $14.00 to $16.00 and gave the company a “buy” rating in a research note on Tuesday, January 14th. Finally, UBS Group upped their target price on shares of Alignment Healthcare from $9.00 to $12.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 30th. One analyst has rated the stock with a sell rating, two have issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $11.88.

Alignment Healthcare Company Profile

Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.